Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia.
OBJECTIVE
To describe the incidence, characteristics, risk factors, and clinical outcome of limbal stem cell deficiency (LSCD) resulting from topical treatment with mitomycin C (MMC) for primary acquired melanosis (PAM) with atypia.


METHODS
Retrospective, observational case series.


METHODS
Patients with LSCD who had been managed with topical MMC for PAM with atypia at the Ocular Oncology Service at the Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, between 2000 and 2007.


METHODS
Retrospective chart review of all patients with PAM with atypia was performed. Impression cytologic analysis of the corneal and conjunctival epithelium was performed in patients suspected of having LSCD.


METHODS
Evaluation of risk factors for LSCD, including demographic characteristics, MMC dosage, and length of treatment; and clinical and visual outcome of patients diagnosed with LSCD.


RESULTS
Limbal stem cell deficiency was identified in 5 (23.8%) of 21 patients. The mean age+/-standard deviation of the 5 patients was 61.8+/-12.7 years compared with 43.7+/-16.1 years in patients in whom this complication did not develop (P = 0.025). Longer treatment periods of MMC were noted in eyes in which LSCD developed (78.4+/-24.8 days) compared with eyes without LSCD (37.7+/-3.1 days; P = 0.07). In 3 patients, spontaneous partial resolution of the LSCD was noted.


CONCLUSIONS
High-dose topical MMC for PAM with atypia may be associated with a relatively high incidence of LSCD. Mitomycin C concentration and treatment regimen should be reevaluated to improve the safety of this treatment protocol.
Lichtinger
Alejandro
A
Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Pe'er
Jacob
J
Frucht-Pery
Joseph
J
Solomon
Abraham
A
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D002452:Cell Count; D003229:Conjunctival Diseases / Q000188:drug therapy*; D003316:Corneal Diseases / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D016850:Limbus Corneae / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008548:Melanosis / Q000188:drug therapy*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D012307:Risk Factors; D013234:Stem Cells / Q000187:drug effects* / Q000473:pathology; D014792:Visual Acuity
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin